EC Number |
Application |
Reference |
---|
3.4.22.15 | diagnostics |
specificity and sensitivity of cathepsin L activity is a diagnostic biomarker for proteinuria |
753941 |
3.4.22.15 | diagnostics |
the enzyme is a candidate antigen to diagnose porcine cysticercosis via ELISA immunoassay |
755642 |
3.4.22.15 | drug development |
a clickable and tagless activity-based probe of cathepsin L probe is a highly effective tool in dissecting cathepsin L biology at the proteome levels in both normal physiology and human diseases, thereby facilitating drug-discovery efforts targeting cathepsin L |
752936 |
3.4.22.15 | drug development |
cathepsins, including cathepsin L, are interesting targets for drug development in an effort to avoid parasite infection or reduce parasite burden and the pathogenic effects of the infection |
755069 |
3.4.22.15 | medicine |
activation of the Nipah virus fusion protein depends on a low pH value and the activity of cathepsin L in host cells |
701389 |
3.4.22.15 | medicine |
cathepsin L expression in cardiomyocytes blunts cardiac hypertrophy through blocking of Akt/GSK3beta signaling. Constitutive cardiac over-expression of cathepsin L in mice attenuates the hypertropic response, markedly reduces apoptosis, and fibrosis |
699624 |
3.4.22.15 | medicine |
cathepsin L inhibition in combination with conventional chemotherapy is a promising therapy in cancer treatment |
712921 |
3.4.22.15 | medicine |
cathepsin L inhibition not only reverses but also prevents the development of drug resistance to doxorubicin, tamoxifen, imatinib, trichostatin A, and flutamide |
710810 |
3.4.22.15 | medicine |
cathepsin L is a potential biomarker for prognosis of nasopharyngeal carcinoma and contributes to nasopharyngeal carcinoma metastasis. Patients with overexpression of cathepsin L in tumor tissue have worse 5-year survival than those without such expression patter |
711945 |
3.4.22.15 | medicine |
cathepsin L is a target in the treatment of patients with metastatic bone disease |
711349 |